Arabic Arabic English English French French German German
dark

ANDA Postapproval Changes: Best Practices and Strategies to Avoid Common Quality Assessment Issues

Niles Ron, PhD, MBA, Branch Chief for the Division of Post-Marketing Activities II, discusses common post-marketing quality assessment issues, strategies to avoid them, and best practices.
Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021
——————– 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training – https://www.fda.gov/cdersbia   
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance  
SBIA Training Resources – https://www.fda.gov/cderbsbialearn  
Twitter – https://twitter.com/FDA_Drug_Info  
Email – CDERSBIA@fda.hhs.gov  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Update on Shared System REMS for Generic Drugs

Next Post

Panel Discussion

Related Posts
Total
0
Share